Acute Myeloid Leukemia Panel by FISH

ARUP LABORATORIES

Patient: [redacted] DOB [redacted] Age: 35 Sex: F **Patient Identifiers:** [redacted] **Visit Number (FIN):** [redacted]	Client: [redacted] Physician: [redacted]	ARUP Test Code: 3016654 Collection Date: 09/26/2023 Received in lab: 09/27/2023 Completion Date: 09/30/2023

Interpretation

Test Performed: Acute Myeloid Leukemia Panel by FISH (FISHAML)
Specimen Type: Bone Marrow
Indication for Testing: AML not having achieved remission

RESULT
Normal FISH Result

inv(3) or t(3;3) RPN1::MECOM Fusion: not detected
Deletion 5q: not detected
Monosomy 7: not detected
Deletion 7q: not detected
t(8;21) RUNX1::RUNX1T1 Fusion: not detected
11p15 (NUP98) Rearrangement: not detected
11q23 (KMT2A) Rearrangement: not detected
inv(16) or t(16;16) CBFB::MYH11 Fusion: not detected

INTERPRETATION
There was no evidence of RPN1::MECOM fusion due to 3q21/3q26.2 inversion or translocation, deletion 5q31, monosomy 7, deletion 7q31, RUNX1::RUNX1T1 fusion due to translocation (8;21)(q21.3;q22), 11p15 (NUP98) rearrangement, 11q23 KMT2A (MLL) rearrangement, or CBFB::MYH11 fusion due to either 16p13.1/16q22 inversion or translocation.

This analysis was performed with the AML panel probes RPN1/MECOM, D5S23/EGR1, D7Z1/D7S486, RUNX1/RUNX1T1 (Abbott Molecular), NUP98 and CBFB-MYH11 (MetaSystems), and MLL (KMT2A) (CytoCell). A total of 200 cells were scored for each probe.

Cytogenomic Nomenclature (ISCN):
nuc
ish(RPN1,MECOM,D5S23,EGR1,D7Z1,D7S486,RUNX1T1,NUP98,KMT2A,MYH11,CBFB,RUNX1)x2[200]

This result has been reviewed and approved by [redacted]

A portion of this analysis was performed at the following location(s):
[redacted]

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

END OF CHART